Johnson & Johnson (JNJ) Finds Support at Key Level Johnson & JohnsonBATS:JNJDEXWireNewsJohnson & Johnson (JNJ) continues to demonstrate strong defensive positioning and renewed momentum as structural shifts in its business and improving sentiment fuel a breakout from a multiyear downtrend. After the successful separation of its consumer health arm, J&J is now more focused on its pharmaceutical and medical technology segments—two higher-margin businesses with long-term growth drivers tied to immunology, oncology, surgical robotics and med-tech innovation. Fundamentally, J&J’s pharma portfolio remains robust, supported by key drugs such as Darzalex, Stelara and Tremfya, with new pipeline readouts expected to broaden the company’s long-term revenue base. Meanwhile, the med-tech division continues to recover as global elective procedures normalize, giving J&J steady top-line expansion despite macro uncertainty. Another important shift is the decreasing overhang from litigation issues—particularly talc claims—which has weighed on the stock for years. As settlements progress and legal clarity improves, investor confidence is returning, contributing to the stock’s recent momentum surge. Additionally, J&J maintains one of the strongest balance sheets in the healthcare sector, with consistent cash flow generation supporting dividends and R&D investment. Technical Outlook The chart shows JNJ breaking strongly above a long-term descending channel that has contained price action since 2022. This breakout, accompanied by rising volume, signals a major trend reversal from a multiyear downtrend to a new bullish phase. Price has also reclaimed a key horizontal level around $185, turning previous resistance into new support. The current momentum suggests JNJ may now target the next major resistance zone near $205–210 phychological high. The RSI remains elevated but healthy, reflecting strong bullish buying without extreme overextension. As long as JNJ holds above the $185 support region, the bullish structure remains intact. Overall, Johnson & Johnson approaches 2026 with improving fundamentals, fading legal risks and a clean technical breakout, creating a constructive setup for continued upside.